Individualised and Equitable Care of Type 2 Diabetes

Informacje na temat projektu

EASY-Diabetes

Identyfikator umowy o grant: 877170

DOI

10.3030/877170

Projekt został zamknięty

Data podpisania przez KE 23 Października 2019

Data rozpoczęcia 1 Listopada 2019

Data zakończenia 29 Lutego 2020

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

ADJUVIA AB
Sweden

Periodic Reporting for period 1 - EASY-Diabetes (Individualised and Equitable Care of Type 2 Diabetes)

Okres sprawozdawczy: 2019-11-01 do 2020-02-29

Podsumowanie kontekstu i ogólnych celów projektu

Diabetes is a common chronic disease that causes suffering for patients and vast costs for society. We have developed an e-health solution for diabetes that aims to improve patient outcomes, save time for healthcare professionals and reduce costs for society. Our SME Phase 1 feasibility study aimed to validate the commercial feasibility of our product with target market segments and key stakeholders. It included financial planning and specification of product features.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

In the project, we have assessed the technical, commercial and financial feasibility of introducing our product to the market. This included identifying features needed for a fully commercialised solution, target markets and stakeholders. We have developed a strategy for introducing our product to the market, including regulatory requirements, operating costs and revenue projections.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

The outcomes of the project resulted in improvements to our plan for the next phase of the business. These improvements include changing some of our target markets, enhancing our implementation models and changing our cooperative strategy. We are thus in a better position to realise the long-term impact of our offering in terms of patient health, healthcare savings and job creation.

Logo for the product